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GUIDELINES
The Use of Chemotherapy in Patients with Advanced
Malignant Pleural Mesothelioma: A Systematic Review and
Practice Guideline
Peter Ellis, MBBS, PhD, FRACP,* Angela M. Davies, MD, FRCPC,†
William K. Evans, MD, FRCPC,* Adam E. Haynes, BSc,‡ Nancy S. Lloyd, BSc,‡
and the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care§
Background: This clinical practice guideline, based on a systematic
review, was developed to determine which chemotherapeutic agents
(or combinations of agents) show the highest response rates, im-
proved survival, quality of life, or symptom control in patients with
advanced malignant pleural mesothelioma.
Methods: A thorough systematic search of the literature was con-
ducted for published articles and conference proceedings for appli-
cable abstracts. Relevant trials, published as articles and abstracts,
were selected and assessed. External feedback was obtained from
Ontario clinicians, and the guideline was approved by the provincial
Lung Cancer Disease Site Group.
Results: One hundred nineteen studies were eligible, including eight
randomized trials and 111 phase II trials. The pooled response rates
from phase II trials suggest that response rates with combination
chemotherapy are higher than with single agents. Data from the
largest randomized controlled trial demonstrated that chemotherapy
with cisplatin and pemetrexed significantly improves response rates
(41% versus 17%, p  0.001), time to progression (5.7 months
versus 3.9 months, p  0.001), and overall survival (median, 12.1
months versus 9.3 months, hazard ratio  0.77, p  0.020) in
comparison to single-agent cisplatin. A second trial demonstrated
cisplatin and raltitrexed significantly improved median survival
compared to single-agent cisplatin (11.4 months versus 8.8 months;
hazard ratio 0.76, p 0.0483). Overall response rate (24% versus
14%, p  0.056) was greater in the combination treatment arm, but
this difference was not statistically significant.
Conclusions: There is good evidence to recommend chemotherapy
with pemetrexed and cisplatin for adult patients with symptomatic
advanced malignant pleural mesothelioma. Such treatment should be
administered with supplementation of vitamin B12 and folic acid. If
pemetrexed is not available, cisplatin plus raltitrexed is a reasonable
alternative.
Key Words: Chemotherapy, Advanced mesothelioma, Systematic
review, Practice guideline, Pleural mesothelioma.
(J Thorac Oncol. 2006;1: 591–601)
Patients with malignant pleural mesothelioma (MPM) gen-erally present with symptomatic advanced disease. Until
recently, there was no standard palliative systemic therapy.
The prognosis for these patients is poor, with several early
retrospective studies reporting 5-year survival rates of
1%1–3 and overall median survivals of 7.6 months1–4 for
patients not receiving chemotherapy. Quality of life (QOL)
can be significantly affected by pain, shortness of breath,
cough, and weight loss, and chemotherapy may offer pallia-
tion of symptoms and improvements in both QOL and
survival.
MPM is an aggressive neoplasm that arises in the
pleura. The unique growth pattern of MPM makes it difficult
to assess tumor response to treatment. Malignant mesotheli-
omas often grow as a “rind’ around the pleural surface, which
may not produce spherical lesions with bidimensional mea-
surements.5 Different criteria have been used for tumor as-
sessment in mesothelioma; however, there is variability be-
tween these criteria. For example, the WHO criteria6 were
developed to assess bidimensionally measurable disease,
whereas the RECIST (Response Evaluation Criteria in
Solid Tumors) criteria7 are more suited to unidimensional
measurements.
The provincial Lung Cancer Disease Site Group iden-
tified a need to summarize the available evidence supporting
the use of chemotherapy for MPM. This systematic review
and practice guideline address the following questions: (1)
Does chemotherapy improve survival, QOL, or symptom
control, compared to best supportive care (BSC)? (2) Which
chemotherapeutic agents (or combinations of agents) have
shown the highest response rates in patients with advanced
MPM?
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Guidelines addressing the role of surgery and radiation
in patients with MPM are available through the Cancer Care
Ontario Web site at www.cancercare.on.ca.
Care has been taken in the preparation of the informa-
tion contained in this guideline. Nonetheless, any clinician
seeking to apply or consult the practice guideline is expected
to use independent medical judgment in the context of indi-
vidual clinical circumstances.
METHODS
This practice guideline was developed by Cancer Care
Ontario’s Program in Evidence-based Care, using the meth-
ods of the Practice Guidelines Development Cycle.8 This
guideline is based on a systematic review and is intended to
promote evidence-based practice.
Literature Search Strategy
Evidence was identified through a systematic search of
MEDLINE (1966 through October of 2005), EMBASE (1980
through October of 2005), CANCERLIT (1966 to March of
2002), and the Cochrane Library databases (2005, issue 3).
Search terms used included “mesothelioma” (medical subject
heading (MeSH) and Excerpta Medica Tree (EMTREE)
term) with and without the subheading “drug therapy,” com-
bined with “drug therapy” (MeSH), “chemotherapy, adju-
vant” (MeSH), and “antineoplastic agents” (MeSH), “chemo-
therapy” (EMTREE), “adjuvant therapy” (EMTREE), and the
text word “mesothelioma.” Those terms were combined with
the search terms for the following study designs and publi-
cation types: practice guidelines; systematic reviews; meta-
analyses; randomized controlled trials; controlled clinical
trials; phase II or III clinical trials; and multicenter or com-
parative studies.
In addition, conference proceedings of the American
Society of Clinical Oncology for the years 1997–2005 were
searched for abstracts of relevant trials. The Canadian Med-
ical Association Infobase (http://mdm.ca/cpgsnew/cpgs/
index.asp) and the National Guidelines Clearinghouse (http://
www.guideline.gov/index.asp) were also searched for exist-
ing evidence-based practice guidelines.
Relevant articles and abstracts were selected and re-
viewed by two reviewers, and the reference lists from these
sources were searched for additional trials, as were the
reference lists from relevant review articles.
Inclusion Criteria
Articles were selected for inclusion in this systematic
review of the evidence if they were practice guidelines,
systematic reviews, or meta-analyses evaluating the use of
chemotherapy for MPM; randomized clinical trials compar-
ing chemotherapy with BSC, or different chemotherapy reg-
imens; phase II clinical trials evaluating chemotherapy, either
as single agents or combinations of agents; or phase II clinical
trials evaluating chemotherapy (single-agent or combination
therapy) combined with immunotherapies such as interferon
and interleukin. Studies including patients with both pleural
and peritoneal malignant mesotheliomas were also consid-
ered eligible for inclusion in this review. Fully published
trials plus abstracts from the proceedings of the American
Society of Clinical Oncology annual scientific meeting were
included. Outcomes of interest included tumor response,
survival, QOL, and symptom control.
Exclusion Criteria
Articles were excluded if they were published in a
language other than English or if they were clinical trials
primarily assessing immunotherapies or trials of multimodal-
ity therapy (chemotherapy combined with surgery and/or
radiation therapy). The literature search for phase II trials was
not updated after April of 2002 as there were data from large
randomized trials with which to make treatment recommen-
dations.
Synthesizing the Evidence
As the chemotherapy regimens involved were hetero-
geneous, the results of the randomized trials were not pooled.
A decision was made to group the phase II trials according to
the following major categories: single-agent chemotherapy,
nonplatinum combinations, single-agent platinum agents,
combination platinum agents, and chemotherapy plus immu-
notherapy. The response rates of the noncomparative trials
were pooled by the formula PRR  (wi RRi )/wi, where
PRR is the pooled response rate of the studies, wi is the
weight of the ith study, and RRi is the response rate of the ith
study.9 RR was calculated by dividing the proportion of
complete or partial responses by the total number of patients
in a study; w was determined by the inverse of the variance
for a study, with the variance calculated by multiplying the
proportion of patients with a complete or partial response
with the proportion of patients with no response and then
dividing the result by the total number of patients in the
study. The 95% confidence interval (CI) for each PRR was
calculated by the formula PRR  1.96 SEPRR, where
SEPRR  (1/wi ).9
External Review and Approval
External review by Ontario practitioners was obtained
through a mailed survey consisting of items that address the
quality of the draft practice guideline report and recommen-
dations and whether the recommendations should serve as a
practice guideline. Final approval of the original guideline
report was obtained from the Practice Guidelines Coordinat-
ing Committee, whose membership included oncologists,
other health providers, patient representatives, and Cancer
Care Ontario executives.
RESULTS
Literature Search Results
Of the relevant studies retrieved (Table 1), eight were
randomized trials10–17 and the remainder were noncomparative
studies: 55 regimens (reported in 52 articles) focused on non–
platinum-based, single-agent chemotherapy18–69; 12 researched
non–platinum-based combination chemotherapy70–81; 35
concentrated on platinum-based chemotherapy82–116; and 12
investigated chemotherapy and immunotherapy.117–128 No ev-
idence-based clinical practice guidelines for the treatment of
mesothelioma were identified, although in 2001 the British
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Thoracic Society published a statement intended to guide the
management of malignant mesothelioma.129 The statement
was developed through a review of literature and expert
consensus; however, a comprehensive and systematic review
of the literature was not attempted, and the British Thoracic
Society indicated that limitations on the quality of evidence
did not allow for the development of recommendations.
A systematic review by Berghmans et al.130 was pub-
lished in 2002 that reviewed the activity of chemotherapy and
immunotherapy on malignant mesothelioma. The review in-
cluded both pleural and peritoneal malignant mesotheliomas
and included searches of the databases of MEDLINE,
HEALTH STAR, and the National Cancer Institute. The
extent of the literature search is not known because a search
strategy was not provided by the authors. The review identi-
fied 83 articles for inclusion, and the authors divided the trials
into the following four groups: cisplatin regimens without
doxorubicin, doxorubicin regimens without cisplatin, regi-
mens containing both cisplatin and doxorubicin, and, finally,
regimens not containing cisplatin or doxorubicin. The current
systematic review has identified more trials than the review
by Berghmans et al.,130 even though the inclusion and exclu-
sion criteria were very similar. Also, the current systematic
review has grouped the trials into their respective drug types,
allowing for a more organized investigation into the action of
different drug types on MPM.
There were no randomized clinical trials of chemother-
apy versus BSC. Two large randomized trials comparing
single-agent cisplatin with a cisplatin combination were iden-
tified. The six remaining randomized trials that compared
chemotherapy regimens were generally small to medium size
and underpowered. Data from all these trials are included.
The majority of trials identified in the literature search
that evaluated systemic therapy for MPM were noncompara-
tive phase II clinical trials. Data from these 111 trials have
been organized into meaningful subgroups, based on the type
of chemotherapy, to allow an exploratory comparison of
response rates between different chemotherapy agents.
Outcomes
The studies in this report exhibited wide variability in
their patient inclusion and exclusion criteria. Almost all the
studies included patients with performance status 0-2. Many
studies allowed the inclusion of patients who had received
previous chemotherapy. Some studies included patients with
measurable or assessable disease, whereas others included
only patients with measurable disease. Additionally, the cri-
teria used to assess response differed across trials, with most
trials using the World Health Organization criteria (bidimen-
sional measurements), and more recent studies using the
RECIST and modified RECIST criteria. Most studies did not
have a central panel review of pathology, and there was
considerable variation between studies in the time from
diagnosis and chemotherapy administration. The QOL mea-
sures used also varied between studies. Many trials included
only patients with MPM, whereas others also included small
numbers of patients with peritoneal mesothelioma. These
differences make statistical comparisons between individual
studies inappropriate. Accordingly, the data have been orga-
nized by grouping together similar study types to provide
aggregate data on response rates where possible. A determi-
nation of the factors that are predictive for those patients
more likely to respond to treatment was considered beyond
the scope of this review.
Randomized Trials
No randomized clinical trials comparing chemotherapy
to BSC were found. Eight published randomized clinical
trials ranging in size from 16 to 456 patients were identi-
fied10–17 (Table 2). Seven of these studies compared different
TABLE 1. Summary of Trials Selected for Inclusion in This Evidence Summary Report
Study type/regimen No. of published studies No. of published abstracts Refs.
Randomized trials 8 0 10–17
Noncomparative studies
Non–platinum-based, single-agent chemotherapy
Temozolomide, ifosfamide, or cyclophosphamide 7 0 18–24
Anthracyclines, liposomal anthracyclines, or mitoxantrone 10 0 25–34
Taxanes 3 1 35–38
Vinca alkaloids 5 0 39–43
Gemcitabine 2 1 44–46
Antimetabolites 7 1 34, 47–53
Topoisomerase inhibitors 3 1 54–57
Experimental agents 9 3 58–69
Non–platinum-based, combination chemotherapy 8 4 70–81
Platinum-based chemotherapy
Single agent 9 0 82–90
Combination regimens 19 7 91–116
Chemotherapy and immunotherapy 12 0 117–128
Total 101a 18
a One noncomparative study (by Colbert et al.33) had two arms of two different drug class regimens and is counted as one study in the total.
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chemotherapy regimens, whereas the eighth study random-
ized patients to receive or not receive an immunomodulator in
addition to chemotherapy.12
In one large randomized study, Vogelzang et al.11
treated 448 eligible patients with either pemetrexed and
cisplatin or cisplatin alone. One hundred eighteen patients
signed informed consent but were not randomized. The rea-
sons for excluding these patients are unclear, and this could
limit the generalizability of the results. The trial design was
modified, after 70 patients were enrolled, to allow all patients
to receive vitamin supplements because of concerns about
excess toxicity in the combination arm. Patients received
vitamin B12 (1000 g every 9 weeks) and folic acid (350–
1000 g/day) supplementation commencing at least 1 week
before chemotherapy. The original sample size was increased
to compensate for that modification. Response rates (41%
versus 17%, p  0.001), time to progression (5.7 versus 3.9
months, p  0.001), and survival (median, 12.1 versus 9.3
months; hazard ratio [HR] 0.77, p  0.020) all favored the
combination. Vitamin supplementation did not appear to
reduce any of the efficacy outcomes. Grade 3 or 4 toxicity
was significantly more frequent in the combined treatment
arm for all hematologic toxicities and nausea, vomiting,
diarrhea, dehydration, and stomatitis. There were fewer drug-
related deaths in the cisplatin arm compared to the combina-
tion arm (4% versus 6%). Patients who received the fully
supplemented regimen experienced lower rates of hemato-
logic toxicity (grade 3 or 4 neutropenia, 23% versus 41%,
p  0.011 or febrile neutropenia, 1% versus 5%, p  0.053,
leukopenia 15% versus 26%, p  0.72) and vomiting (11%
versus 21%, p 0.071) than those who received partial or no
supplementation. The Lung Cancer Symptom Scale was used
to assess QOL, and data were presented at the American
Society of Clinical Oncology meeting in 2002. Dyspnea and
pain were significantly improved for patients receiving pem-
etrexed and cisplatin after six cycles of treatment (p  0.004
and p  0.017), respectively.131,132
In another large phase III trial reported by Van Meer-
beeck et al.,10 250 patients were randomized to receive either
raltitrexed and cisplatin or cisplatin alone. The median num-
ber of cycles of raltitrexed/cisplatin administered was five
(range, one to 10). Median survival was 11.4 for the combi-
nation versus 8.8 months for single-agent cisplatin (HR 
0.76, p  0.0483). Overall response rates (24% versus 14%,
p  0.056) and progression free survival (5.3 versus 4.0
months, HR  0.78, p  0.058) were greater in the combi-
nation treatment arm, but neither difference achieved conven-
tional statistical significance. More patients in the combina-
tion group developed neutropenia (16% versus 8%), fatigue
(12% versus 6%), nausea (14% versus 10%), and vomiting
(13% versus 7%). There was no statistically significant dif-
ference in global QOL between the two groups (details of
data not provided).
Samson et al.15 randomized 96 patients to receive
chemotherapy with cyclophosphamide, doxorubicin, and im-
idazole carboxamide or cyclophosphamide and doxorubicin
alone. There were no significant differences in response rate
(13% versus 11%), median time to disease progression (2.1
months versus 3.2 months), or median survival (5.5 months
versus 6.7 months), respectively. Chahinian et al.14 random-
ized 79 patients to cisplatin with either mitomycin or doxo-
rubicin. The response rate for the cisplatin-mitomycin com-
bination was greater than that for the doxorubicin-cisplatin
combination (26% versus 14%). Median time to treatment
failure (3.6 versus 4.8 months, respectively, p  0.59) and
median survival (7.7 versus 8.8 months, p  0.75) were
similar between the two treatment groups.
The remaining four studies included only small num-
bers of patients and lacked the power to reach any meaningful
conclusions. Sorensen et al.17 randomized 31 patients to
either doxorubicin or cyclophosphamide as single agents. No
objective responses were observed in either treatment arm.
White et al.13 randomized 25 patients with MPM along with
95 non-small cell lung cancer patients to either cisplatin and
etoposide or infusional carboplatin. No objective responses
were observed with the infusional carboplatin (8% versus
0%, respectively); however, survival for the two treatment
arms was similar (4.3 months versus 5.0 months). O’Brien et
al12 found no benefit from the addition of SRL172 (Myco-
bacterium vaccae) to combination chemotherapy, and Cant-
well et al.16 observed no activity of an experimental platinum
analogue, JM9, in comparison to carboplatin (response rate,
0% versus 22%, respectively).
Noncomparative Studies
The pooled response rates for phase II trials are sum-
marized in Table 3. More detailed data on these trials can be
found in the full evidence-based report available on the
Cancer Care Ontario Web site at www.cancercare.on.ca/.
Non–platinum-based Single-agent Chemotherapy
A large number of phase II trials of single-agent che-
motherapy were identified, totaling 1673 patients enrolled in
52 trials of various agents.18–69 However, these studies pro-
vide weak evidence on which to base decisions about sys-
temic therapy for MPM. In view of the heterogeneous nature
of these phase II trials, the studies were separated into
subgroups based on the type of chemotherapy evaluated in
the trial (alkylating agents, anthracyclines, taxanes, vinca
alkaloids, gemcitabine, antimetabolites, topoisomerase inhib-
itors, and experimental agents), and an aggregate response
rate was determined for each group.
Alkylating Agents. Seven trials involving 194 patients used
temozolomide, ifosfamide, or cyclophosphamide in differing sched-
ules.18–24 The combined intention-to-treat (ITT) response rate
for those trials was 4.6% (95% CI: 1.8%–7.5%). Grade 3 and 4
neutropenia ranged from 7% to 50%, and there were four
treatment-related deaths. Other frequent toxicities included nau-
sea, vomiting, and neurologic toxicity (encephalopathy).
Anthracyclines. Ten phase II studies involving 319
patients evaluated conventional anthracyclines, liposomal an-
thracyclines, and mitoxantrone.25–34 Response rates varied
from 0% to 26%, with an overall ITT response rate of 6.1%
(95% CI: 3.6%–8.7%). Major toxicities included neutrope-
nia, nausea and vomiting, and skin toxicity (with liposomal
preparations). No formal QOL measures were included, but
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Colbert et al.33 reported that 53% of patients with chest pain
reported improvement in that symptom with treatment.
Taxanes. Four studies including 111 patients examined
taxanes as a single-agent chemotherapy.35–38 With the excep-
tion of one study by Vorobiof et al.,35 the response rates were
10% (overall ITT response rate, 5.1% [95% CI: 1.2%–
9.1%]). Seven deaths due to treatment were observed. No
study evaluated patient QOL.
Vinca Alkaloids. Five studies involving 115 patients
tested vinca alkaloids.39–43 The overall ITT response rate was
3.6% (95% CI: 0.4%–6.8%). Steele et al.39 observed an ITT
response rate of 24% with single-agent vinorelbine and a high
rate of grade 3 and 4 neutropenia (62%). Other major toxic-
ities included constipation (10%) and phlebitis (14%). QOL
was assessed using the Rotterdam Symptom Checklist. Im-
provements were seen in lung symptoms (48%), physical
symptoms (41%), and psychological well-being (76%). Little
activity was seen in the four trials evaluating older vinca
alkaloids.40–43
Gemcitabine. Three trials examined gemcitabine as a
single-agent chemotherapy.44–46 Response rates varied from
0% to 31% with a combined ITT response rate of 6.7% (95%
CI: 1.2%–12.2%), and median survival ranged from 4.7 to 8
months.
Antimetabolites. Nine regimens reported in eight papers
evaluated a variety of antimetabolites.34,47–53 A total of 319
patients were included in those studies, with an overall ITT
response rate of 9.0% (95% CI: 6.0%–11.9%). Only one
study by Scagliotti et al.49 assessed QOL, using the Lung
Cancer Symptom Scale. The authors reported an improve-
ment in the patient-reported global QOL as well as the
observer-reported total score for those patients who re-
sponded to treatment.
Topoisomerase Inhibitors. Topoisomerase inhibitors
were evaluated in five regimens reported in four articles.54–57
There was no observed activity with either topotecan or
irinotecan and minimal activity with etoposide as a single
agent (ITT response, 4.9% [95% CI: 1.0%–8.8%]).
Experimental Agents. Little activity was observed with
the experimental agents evaluated in 12 phase II trials.58–69
Mikulski et al.61 conducted a large phase II trial (105 patients)
using ranpirnase and obtained an ITT response rate of 3.8%
with a median survival of 6 months. That agent has been
taken into phase III trials for evaluation.
Non–platinum-based Combination Chemotherapy
Twelve trials have evaluated non–cisplatin-containing
chemotherapy combinations.70–81 Non–cisplatin-containing
combinations appear to have a small increase in activity in
comparison to single agents. The overall ITT response rate
for those trials was 10.4% (95% CI: 6.8%–14.1%) compared
to 6.4% (95% CI: 5.3%–7.5%) for single agents. Seven of the
TABLE 3. Phase II Noncomparative Studies: Pooled Response Rates
Study type/regimen
No. of
published studies/
abstracts
No. of
patients
enrolled
Pooled ITT response
rate (95% CI) Refs.
Noncomparative studies
Non–platinum-based, single-agent chemotherapy
Alkylating agents(temozolomide, ifosfamide, or cyclophosphamide) 7 194 4.6% (1.8%–7.5%) 18–24
Anthracyclines, liposomal anthracyclines, or mitoxantrone 10 319 6.1% (3.6%–8.7%) 25–34
Taxanes 4 111 5.1% (1.2%–9.1%) 35–38
Vinca alkaloids 5 115 3.6% (0.4%–6.8%) 39–43
Gemcitabine 3 72 6.7% (1.2%–12.2%) 44–46
Antimetabolites 8 319 9.0% (6.0%–11.9%) 34,47–53
Topoisomerase inhibitors 4 117 4.9% (1.0%–8.8%) 54–57
Experimental agents 12 376 4.0% (2.0%–5.9%) 58–69
Non–platinum-based combination chemotherapy
Anthracycline regimens 7 130 11.7% (6.3%–17.1%) 70–76
Other regimens 5 117 9.4% (4.4%–14.3%) 77–81
Overall 12 247 10.4% (6.8%–14.1%) 70–81
Platinum-based chemotherapy
Single agent: cisplatin 5 108 20.0% (12.8%–27.2%) 82–86
Single agent: carboplatin 3 89 10.1% (3.9%–16.3%) 87–89
Single agent: overall 9 197 14.3% (9.6%–19.0%)a 82–90
Combination regimens 19 790 24.9% (22.0%–27.9%) 91–116
Chemotherapy and immunotherapy
Non–platinum-based chemotherapy 3 72 11.2% (4.2%–18.2%) 117–119
Single-agent platinum chemotherapy 5 129 19.9% (13.2%–26.5%) 120–124
Combination platinum-based chemotherapy 4 135 8.8% (4.3%–13.2%) 125–128
Overall 12 336 12.0% (8.7%–15.3%) 117–128
ITT, intention to treat; CI, confidence interval. a Pooled response rate excludes study evaluating experimental platinum analogues.90
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trials contained an anthracycline.70–76 Grade 3 to 4 neutrope-
nia occurred in 7% to 87% of patients, with five studies
reporting rates of 27% or higher.72,73,77,79
Platinum-based Single-agent and Combination
Chemotherapy
A total of 35 trials have evaluated a platinum analogue in
the treatment of patients with malignant mesothelioma.82–116
These trials vary in the treatment strategy (chemotherapy as
either a single agent82–90 or in combination91–116), route of
administration (intrapleural versus intravenous), and type of
platinum analogue (cisplatin versus carboplatin versus oxali-
platin versus experimental platinum analogues).
There were nine trials of single-agent chemotherapy
(five cisplatin, three carboplatin, and one platinum analogue
ZD0473).82–90 Platinum analogue ZD0473 was evaluated in a
study by Giaccone et al.90 and demonstrated no activity in
MPM. The response rate to single-agent cisplatin was higher
than carboplatin (ITT response: 20.0% versus 10.1%, respec-
tively); however, these results were derived from only 197
patients in total and there was overlap of the 95% CIs for
these values. Toxicity was not well documented in the single-
agent cisplatin trials. However, Planting et al.82 reported that
70% of patients had grade 3 to 4 thrombocytopenia and 14%
had grade 3 neutropenia. Rebattu et al.83 reported that 46% of
patients had grade 3 to 4 nausea and/or vomiting, and 8% had
grade 3 leukopenia.
More trials with greater numbers of patients (790 pa-
tients in total) have evaluated cisplatin in combination with
other drugs.91–116 The pooled data suggest that combining
cisplatin with other drugs does not improve the response rate
greatly. The overall ITT response rate for platinum combi-
nations was 24.9% (95% CI: 22.0%–27.9%). The highest
response rates were observed when a platinum agent was
combined with an anthracycline (combined ITT response
rate, 32.4% [95% CI: 25.6%–39.2%]) or either gemcitabine
or irinotecan (combined ITT response rate, 26.1% [95% CI:
21.5%–30.7%]). Formal QOL was conducted in the study by
Nowak et al.106 The authors reported that those patients who
responded had greater improvement on the European Organi-
sation for Research and Treatment of Cancer-Quality of Life
Questionnaire-Cancer global QOL scale compared to those
who did not respond (p  0.006); however, the effect did not
persist past the completion of treatment. Pennucci et al.,92
Breau et al.,95 Ardizzoni et al.,96 Middleton et al.,101 Favaretto
et al.,104 Pinto et al.,105 Byrne et al.,108 and Kasseyet et al.109
all observed improvements in symptoms in responding pa-
tients as well as in some patients with stable disease. High
levels of hematologic toxicity were reported in most trials.
Additional toxicities included grade 3 to 4 nausea/vomiting in
12% to 77% of patients, grade 3 diarrhea in 2% to 10% of
patients, grade 3 to 4 infection in 4% to 9% of patients, and
two renal toxicities,95,97 with one of these patients suffering
renal failure.97
Combination Chemotherapy and Immunotherapy
There have been 12 studies combining chemotherapy
with an immunomodulator such as interferon and interleu-
kin.117–128 Chemotherapy regimens in nine of the 12 studies
have included cisplatin or carboplatin.120–128 The overall ITT
response rate was 12.0% (95% CI: 8.7%–15.3%). Response
rates for combination chemotherapy and interferon were
similar to those for single-agent chemotherapy and interferon.
Additional toxicities from the addition of interferon or inter-
leukin included asthenia and fever. None of the studies
assessed QOL, and only one study121 made reference to
symptom improvement.
External Review
Feedback on a draft version of this report was obtained
through a mail survey of Ontario practitioners. The sample
included surgeons, respirologists, and medical and radiation
oncologists. Of the 141 surveys sent, 59 responses (42%)
were received. Thirty-five (59%) of the practitioners who
responded indicated that the report was relevant to their
clinical practice. From this group of respondents, 21 (62%)
indicated that this type of evidence summary would be useful
for clinical decision making. The guideline was also reviewed
and approved by the Practice Guidelines Coordinating Com-
mittee. Comments received through external review were
incorporated into the practice guideline.
DISCUSSION
No studies comparing chemotherapy to BSC for pa-
tients with MPM were identified. Therefore, there is no
evidence to answer the question of whether palliative chemo-
therapy improves survival in comparison to BSC for patients
with MPM. Similarly, there is no level I or II evidence
demonstrating that palliative chemotherapy improves QOL in
comparison to BSC for patients with MPM. However, evi-
dence from two large randomized trials comparing single-
agent chemotherapy to combination chemotherapy showed
significantly improved survival with combination chemother-
apy. As single-agent cisplatin is unlikely to reduce survival in
this patient population, these studies provide indirect evi-
dence of a survival and QOL benefit from chemotherapy for
patients with MPM. Further evidence comes from a recently
published small trial that did not meet the inclusion criteria
for this review, in which patients with MPM were random-
ized to immediate versus delayed chemotherapy. Patients
randomized to immediate chemotherapy had a small im-
provement in survival (14 versus 10 months, respectively),
but this was not statistically significant.133
A wide variety of agents have been tested either singly
or in combination in patients with MPM. In uncontrolled
studies, combination chemotherapy regimens appear to have
slightly higher response rates than single-agent chemother-
apy. The highest response rates have been seen with plati-
num-based chemotherapy regimens. Cisplatin as a single
agent has a higher response rate than carboplatin. Based on
those phase II data, cisplatin is the preferred platinum agent
for use in the treatment of MPM. There is no evidence to
support the addition of interferon or interleukin to chemo-
therapy in patients with MPM. Such combinations appear no
more active than cisplatin-based chemotherapy but are asso-
ciated with additional toxicity from the interferon or inter-
leukin.
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CONCLUSION
Before 2003, there was no standard chemotherapy reg-
imen for the treatment of patients with malignant mesotheli-
oma. The results of one large randomized trial presented at
the 2002 meeting of American Society of Clinical Oncology,
and subsequently published,11 make it reasonable to consider
pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 3
weeks, with vitamin supplementation with B12 1000 g
monthly and folic acid 0.4 to 1.0 mg in the treatment of
patients with symptomatic MPM who are of good perfor-
mance status (ECOG 0-1). Both vitamin supplements should
be started before the administration of pemetrexed. Another
recently published randomized study10 comparing cisplatin
and raltitrexed to cisplatin alone has demonstrated superior
survival for this combination regimen but nonsignificant
improvements in response rate and progression-free survival.
Therefore, the evidence supporting the use of cisplatin and
pemetrexed is stronger. However, it is reasonable to consider
the use of raltitrexed 3 mg/m2 and cisplatin 80 mg/m2 every
3 weeks, if pemetrexed is not available. The routine substi-
tution of carboplatin for cisplatin is not recommended. Prac-
titioners should select therapy based on the treatment options
available, convenience, goals of therapy, and potential ad-
verse effects. Given the limited amount of high-quality evi-
dence on the role of chemotherapy in MPM and the poor
treatment results for this disease, patients with mesothelioma
should still be encouraged to participate in clinical trials of
treatment for this disease.
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